Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity

Circ Heart Fail. 2017 Nov;10(11):e004478. doi: 10.1161/CIRCHEARTFAILURE.117.004478.
No abstract available

Keywords: cardiomyopathies; death, sudden, cardiac; defibrillators, implantable; heart failure.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Aminobutyrates / therapeutic use
  • Angiotensin Receptor Antagonists / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Biphenyl Compounds
  • Clinical Decision-Making
  • Conservative Treatment
  • Death, Sudden, Cardiac / etiology
  • Death, Sudden, Cardiac / prevention & control*
  • Defibrillators, Implantable*
  • Drug Combinations
  • Heart Failure / complications
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Humans
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Practice Guidelines as Topic
  • Stroke Volume*
  • Tetrazoles / therapeutic use
  • Time Factors
  • Time-to-Treatment
  • Valsartan
  • Ventricular Remodeling

Substances

  • Adrenergic beta-Antagonists
  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Biphenyl Compounds
  • Drug Combinations
  • Mineralocorticoid Receptor Antagonists
  • Tetrazoles
  • Valsartan
  • sacubitril and valsartan sodium hydrate drug combination